TRIple assay Of rectal Mucus In the diagnosis of Colorectal cancer
Research type
Research Study
Full title
Development of a multiomics assay for use on Sponsor sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway. (TRIOMIC) TRIOMIC TRIple assay Of rectal Mucus In the diagnosis of Colorectal cancer.
IRAS ID
342871
Contact name
Hugo Lywood
Contact email
Sponsor organisation
Origin Sciences Ltd
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
A mucus sample is collected from the back passage (rectum) using the OriCol™ Sampling Device. Origin Sciences will use the results from the rectal mucus sample together with other results from tests of interest collected from the patient e.g. blood, and any tissue biopsy (FFPE). They hope to find out whether these samples give better and quicker results, which will help doctors to diagnose colorectal diseases in the future. This approach may result in patients not needing more invasive investigations for diagnosis (e.g. colonoscopy).
6600 participants will be enrolled.
Patients, referred by their GP on an urgent suspected bowel cancer pathway, will be seen in a community diagnostic centre or ‘diagnostic hub’. The diagnostic hub is not a hospital but is a clinical building staffed by trained healthcare professionals. Patients will be seen by a highly trained bowel cancer nurse specialist who will ask the patient detailed questions about their symptoms, examine the patient and refer them for the most appropriate test. We predict that by assessing patients outside of the hospital they will be seen and also get their test (colonoscopy or CT scan) quicker than is currently the case.
Because the community diagnostic centre is not at the hospital, the clinic will be far less busy and other things like car parking will be much easier than at the hospital.
Because all patients will be assessed the same way, the system will be easier to manage and patients will be less likely to be sent for an inappropriate colonoscopy.
Patients who have a bowel cancer detected will be treated in exactly the same way as is currently the case. Other tests will be arranged as needed and a referral will immediately be made to a consultant at the hospital as per standard of care.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
24/EM/0180
Date of REC Opinion
14 Oct 2024
REC opinion
Further Information Favourable Opinion